Published in J Biol Inorg Chem on September 05, 2006
Enzymatic processing of platinated RNAs. J Am Chem Soc (2010) 0.85
Binding of kinetically inert metal ions to RNA: the case of platinum(II). Met Ions Life Sci (2011) 0.81
DNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular Consequences. J Nucleic Acids (2010) 0.81
Rapid cross-linking of an RNA internal loop by the anticancer drug cisplatin. J Am Chem Soc (2009) 0.81
Cisplatin and siRNA interference with structure and function of Wnt-5a mRNA: design and in vitro evaluation of targeting AU-rich elements in the 3' UTR. J Biol Inorg Chem (2007) 0.81
Cisplatin Targeting of Bacterial Ribosomal RNA Hairpins. Int J Mol Sci (2015) 0.77
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Direct chemical method for sequencing RNA. Proc Natl Acad Sci U S A (1979) 25.15
The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides. Q Rev Biophys (1978) 14.75
INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE. Nature (1965) 6.02
Platinum compounds: a new class of potent antitumour agents. Nature (1969) 5.92
Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature (1995) 3.67
Metal ions and RNA folding: a highly charged topic with a dynamic future. Curr Opin Chem Biol (2005) 3.00
Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol (2001) 2.56
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature (1999) 2.35
Molecular electrostatic potential of the nucleic acids. Q Rev Biophys (1981) 2.29
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem (2005) 2.24
Monte Carlo description of oligoelectrolyte properties of DNA oligomers: range of the end effect and the approach of molecular and thermodynamic properties to the polyelectrolyte limits. Proc Natl Acad Sci U S A (1989) 2.11
Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst (1990) 2.06
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res (2002) 1.98
Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry (1983) 1.96
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther (2004) 1.82
Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res (2000) 1.70
Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in virtro. Int J Cancer (1970) 1.64
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol (2005) 1.61
AFV1, a novel virus infecting hyperthermophilic archaea of the genus acidianus. Virology (2003) 1.56
Metal ion binding to catalytic RNA molecules. Curr Opin Struct Biol (2003) 1.51
Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep (2005) 1.50
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res (2004) 1.49
Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat (2005) 1.49
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res (2004) 1.44
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res (1993) 1.42
Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents (2005) 1.42
Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer? Nat Clin Pract Oncol (2005) 1.40
Importance of coulombic end effects on cation accumulation near oligoelectrolyte B-DNA: a demonstration using 23Na NMR. Biophys J (1995) 1.25
Interaction of cis-dichlorodiammineplatinum (II) with DNA. Biochim Biophys Acta (1971) 1.24
Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res (1992) 1.21
Grand canonical Monte Carlo molecular and thermodynamic predictions of ion effects on binding of an oligocation (L8+) to the center of DNA oligomers. Biophys J (1995) 1.21
Approach to the limit of counterion condensation. Biopolymers (1990) 1.20
Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation. Nucleic Acids Res (1982) 1.20
Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res (1993) 1.20
Tick-borne viruses structurally similar to Orthomyxoviruses. Virology (1983) 1.12
Multinuclear NMR studies of DNA hairpins. 1. Structure and dynamics of d(CGCGTTGTTCGCG). Biochemistry (1989) 1.07
Large electrostatic differences in the binding thermodynamics of a cationic peptide to oligomeric and polymeric DNA. Proc Natl Acad Sci U S A (1996) 1.02
Metal ion-binding properties of (N3)-deprotonated uridine, thymidine, and related pyrimidine nucleosides in aqueous solution. Proc Natl Acad Sci U S A (2005) 1.02
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J Inorg Biochem (1999) 1.02
Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl Acad Sci U S A (2005) 1.00
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs (2005) 0.98
Cisplatin-induced post-translational modification of histones H3 and H4. J Biol Chem (2004) 0.94
DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents. Curr Top Med Chem (2005) 0.93
Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs (2005) 0.90
Crystal structure of 2'-O-Me(CGCGCG)2, an RNA duplex at 1.30 A resolution. Hydration pattern of 2'-O-methylated RNA. Nucleic Acids Res (1997) 0.90
Recent advances in the treatment of testicular cancer. Expert Rev Anticancer Ther (2005) 0.90
Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res (1989) 0.88
Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res (1994) 0.88
Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem (2004) 0.87
Novel concepts in the development of platinum antitumor drugs. Curr Med Chem Anticancer Agents (2002) 0.87
DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. Eur J Biochem (1998) 0.86
Multinuclear NMR studies of DNA hairpins. 2. Sequence-dependent structural variations. Biochemistry (1989) 0.86
Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. Proc Natl Acad Sci U S A (1995) 0.85
Kinetic preference for interaction of cisplatin with the G-C-rich wobble basepair region in both tRNAAla and MhAla. Dalton Trans (2006) 0.83
Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells. Ultrastruct Pathol (2002) 0.83
New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs (2005) 0.82
Preclinical perspectives on the use of platinum compounds in cancer chemotherapy. Semin Oncol (2004) 0.82
cis-Diamminedichloroplatinum(II) selectively cross-links high mobility group proteins 1 and 2 to DNA in micrococcal nuclease accessible regions of chromatin. Biochem Biophys Res Commun (1987) 0.82
Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs (2006) 0.81
Electronic tuning of the lability of Pt(II) complexes through pi-acceptor effects. Correlations between thermodynamic, kinetic, and theoretical parameters. Inorg Chem (2003) 0.81
Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin. J Biol Inorg Chem (2003) 0.80
The effect of chromatin structure on cisplatin damage in intact human cells. Nucleic Acids Res (2000) 0.80
Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. Exp Cell Res (2003) 0.79
Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction. Int J Cancer (2000) 0.78
A combination of access to preassociation sites and local accumulation tendency in the direct vicinity of G-N7 controls the rate of platination of single-stranded DNA. Dalton Trans (2005) 0.78
Medium Effects on Reactivity Profiles for Platination of Phosphorothioate-Containing Oligonucleotides. Inorg Chem (1999) 0.78
Cisplatin-induced apoptosis in cultures of human Schwann cells. Neurosci Lett (2005) 0.78
A copper connection to the uptake of platinum anticancer drugs. Proc Natl Acad Sci U S A (2002) 0.77
Kinetics and mechanism for platination of thione-containing nucleotides and oligonucleotides: evaluation of the salt dependence. J Biol Inorg Chem (2002) 0.75
Combination therapy versus single agent chemotherapy in non-small cell lung cancer. Expert Opin Pharmacother (2005) 0.75
Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol (2002) 1.42
Design of novel antibiotics that bind to the ribosomal acyltransfer site. J Am Chem Soc (2002) 1.23
Effects of nucleotide substitution and modification on the stability and structure of helix 69 from 28S rRNA. RNA (2005) 1.06
pH-dependent structural changes of helix 69 from Escherichia coli 23S ribosomal RNA. RNA (2008) 0.98
Identification of a new alpha1,2-fucosyltransferase involved in O-antigen biosynthesis of Escherichia coli O86:B7 and formation of H-type 3 blood group antigen. Biochemistry (2008) 0.93
Synthesis of helix 69 of Escherichia coli 23S rRNA containing its natural modified nucleosides, m(3)Psi and Psi. J Org Chem (2002) 0.93
Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg Med Chem (2007) 0.92
Pseudouridines in rRNA helix 69 play a role in loop stacking interactions. Org Biomol Chem (2008) 0.91
Probing conformational states of modified helix 69 in 50S ribosomes. J Am Chem Soc (2011) 0.90
Identification and role of functionally important motifs in the 970 loop of Escherichia coli 16S ribosomal RNA. J Mol Biol (2007) 0.90
A new role for cisplatin: probing ribosomal RNA structure. Chem Commun (Camb) (2008) 0.89
Characterization of a novel alpha1,2-fucosyltransferase of Escherichia coli O128:b12 and functional investigation of its common motif. Biochemistry (2007) 0.88
Comparison of solution conformations and stabilities of modified helix 69 rRNA analogs from bacteria and human. Biopolymers (2011) 0.87
Role of pseudouridine in structural rearrangements of helix 69 during bacterial ribosome assembly. ACS Chem Biol (2012) 0.87
Solution conformations of two naturally occurring RNA nucleosides: 3-methyluridine and 3-methylpseudouridine. Bioorg Med Chem (2005) 0.86
Structure modulation of helix 69 from Escherichia coli 23S ribosomal RNA by pseudouridylations. Nucleic Acids Res (2013) 0.84
Selection of peptides that target the aminoacyl-tRNA site of bacterial 16S ribosomal RNA. Biochemistry (2009) 0.84
Ligand- and pH-induced conformational changes of RNA domain helix 69 revealed by 2-aminopurine fluorescence. Angew Chem Int Ed Engl (2012) 0.83
Kinetic preference for interaction of cisplatin with the G-C-rich wobble basepair region in both tRNAAla and MhAla. Dalton Trans (2006) 0.83
Synthesis and solution conformation studies of 3-substituted uridine and pseudouridine derivatives. Bioorg Med Chem (2007) 0.82
Selection of peptides targeting helix 31 of bacterial 16S ribosomal RNA by screening M13 phage-display libraries. Molecules (2011) 0.81
Cisplatin and siRNA interference with structure and function of Wnt-5a mRNA: design and in vitro evaluation of targeting AU-rich elements in the 3' UTR. J Biol Inorg Chem (2007) 0.81
Single-molecule FRET reveals a cooperative effect of two methyl group modifications in the folding of human mitochondrial tRNA(Lys). Chem Biol (2011) 0.81
Synthesis and solution conformation studies of the modified nucleoside N(4),2'-O-dimethylcytidine (m(4)Cm) and its analogues. Bioorg Med Chem (2008) 0.81
Platinum interference with siRNA non-seed regions fine-tunes silencing capacity. J Am Chem Soc (2011) 0.78
Platination of the siRNA sense-strand modulates both efficacy and selectivity in vitro. Biochem Biophys Res Commun (2007) 0.78
Synthesis of a 3-methyluridine phosphoramidite to investigate the role of methylation in a ribosomal RNA hairpin. Bioorg Med Chem (2002) 0.78
A combination of access to preassociation sites and local accumulation tendency in the direct vicinity of G-N7 controls the rate of platination of single-stranded DNA. Dalton Trans (2005) 0.78
Amino acid-linked platinum(II) analogues have altered specificity for RNA compared to cisplatin. Chem Commun (Camb) (2014) 0.77
Time dependence of cisplatin-induced duplex dissociation of 15-mer RNAs and mature miR-146a. Dalton Trans (2013) 0.77
Probing RNA hairpins with cobalt(III)hexammine and electrospray ionization mass spectrometry. J Am Soc Mass Spectrom (2006) 0.77
A modified fluorescent intercalator displacement assay for RNA ligand discovery. Anal Biochem (2010) 0.77
Selection of heptapeptides that bind helix 69 of bacterial 23S ribosomal RNA. Bioorg Med Chem (2013) 0.77
Construction of polyamine-modified uridine and adenosine derivatives--evaluation of DNA binding capacity and cytotoxicity in vitro. Bioorg Med Chem (2007) 0.76
NMR conformational analysis of p-tolyl furanopyrimidine 2'-deoxyribonucleoside and crystal structure of its 3',5'-di-O-acetyl derivative. Bioorg Med Chem (2005) 0.76
Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. J Immunol Methods (2005) 0.76
Probing the stabilizing effects of modified nucleotides in the bacterial decoding region of 16S ribosomal RNA. Bioorg Med Chem (2013) 0.75
{1-[1-(3-Carboxy-propanamido)eth-yl]-1',2-bis-(diphenyl-phosphino)ferrocene-κP,P'}dichloridoplatinum(II) dichloro-methane 1.25-solvate. Acta Crystallogr Sect E Struct Rep Online (2007) 0.75
Synthesis and characterization of modified nucleotides in the 970 hairpin loop of Escherichia coli 16S ribosomal RNA. Bioorg Med Chem (2009) 0.75
Expression and in vivo characterization of the antimicrobial peptide oncocin and variants binding to ribosomes. Biochemistry (2020) 0.75
Kinetics of cisplatin binding to short r(GG) containing miRNA mimics - influence of Na(+)versus K(+), temperature and hydrophobicity on reactivity. Dalton Trans (2015) 0.75
Pseudouridine modifications influence binding of aminoglycosides to helix 69 of bacterial ribosomes. Org Biomol Chem (2017) 0.75
Cisplatin-induced duplex dissociation of complementary and destabilized short GG-containing duplex RNAs. Dalton Trans (2014) 0.75
Design, synthesis and DNA interactions of a chimera between a platinum complex and an IHF mimicking peptide. Org Biomol Chem (2015) 0.75
The polyamines spermidine and spermine retard the platination rate of single-stranded DNA oligomers and plasmids. J Inorg Biochem (2007) 0.75
Expanding the chemical nature of siRNAs: oxaliplatin as metalation reagent. Biochem Biophys Res Commun (2008) 0.75
Electrochemical and spectroscopic evidences of the interaction between DNA and Pt(II)(dppf)-complex. Biometals (2008) 0.75
A comparative kinetic study of modified Pt(dppf)Cl2 complexes and their interactions with L-cys and L-met. Dalton Trans (2005) 0.75
Kinetics and mechanism for platination of thione-containing nucleotides and oligonucleotides: evaluation of the salt dependence. J Biol Inorg Chem (2002) 0.75
Synthesis of 15N-enriched pseudouridine derivatives. Org Lett (2003) 0.75
Light-induced anticancer activity of [RuCl2(DMSO)4] complexes. J Med Chem (2005) 0.75